Value through Innovation

main navigation

jump to content to meta navigation
Headillu

page content

jump to main navigation to meta navigation

Boehringer Ingelheim Press Releases

See the latest Boehringer Ingelheim news releases. To quickly find all news releases on a specific topic, please use the fulltext search.

Press Release Archive

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
23.10.2008 Telmisartan (Micardis®) as effective as ramipril but with better long-term tolerability in high-risk cardiovascular Asian patients - For medical media, outside the US only
22.10.2008 From Curiosity to Discovery:
Boehringer Ingelheim broadens oncology pipeline with promising new data for potentially first in class Plk1 inhibitor - For medical media, outside the US only
17.10.2008 From Curiosity to Discovery:
Boehringer Ingelheim`s pipeline update unveils novel investigational compounds heralding the Company`s entry into Type 2 Diabetes
06.10.2008 ERS COPD Research Award 2008 sponsored by Boehringer Ingelheim
05.10.2008 COPD landmark trial UPLIFT® proves tiotropium sustains lung function improvements over four years and improves survival rate - For medical media, outside the US only
02.10.2008 Boehringer Ingelheim signs a license agreement with Evec Inc. for its fully-human antibody programme
25.09.2008 Recent research shows significant benefits in acute ischaemic stroke with Actilyse® beyond currently approved three hour treatment window - For medical media, outside the US only
24.09.2008 Positive UK health technology appraisal for novel oral anticoagulant Pradaxa® (dabigatran etexilate) - For medical media, outside the US only
24.09.2008 Landmark UPLIFT® study reaffirms the safety of Spiriva® (tiotropium) in patients with Chronic Obstructive Pulmonary Disease
23.09.2008 Established safety profile of Spiriva® confirmed by 30 rigorously controlled clinical trials - For medical media, outside the US only
04.09.2008 Landmark research heralds new era in dog heart treatment and longer life for dogs
31.08.2008 First landmark ARB trial against placebo shows Micardis® (telmisartan) reduces the risk of cardiovascular death, heart attack and stroke in ACE-intolerant high-risk patients - For medical media, outside the US only
26.08.2008 Pramipexole clinical trial programme in Restless Legs Syndrome (RLS) reveals new significant results
25.08.2008 Role of pramipexole in key research areas of Parkinson’s disease management discussed at 12th EFNS Congress - For medical media, outside the US only
25.08.2008 Boehringer Ingelheim to sign cooperation with HISOAR in China
21.08.2008 Cymbalta receives european approval for the treatment of Generalised Anxiety Disorder
19.08.2008 New data show Duloxetine maintained pain reduction for more than six months in patients with diabetic peripheral neuropathic pain
07.08.2008 Spiriva®, Micardis® and Flomax® - Boehringer Ingelheim`s highly successful products show good growth. Excellent progress in Research and Development. Strong euro curbs growth. Expenditure in R&D+M reduces operating income.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
back to top

Contact

Boehringer Ingelheim GmbH

Corporate Headquarters
Binger Str. 173
55216 Ingelheim
Germany


Phone +49 / 6132 / 77 0
Fax +49 / 6132 / 72 0

media contacts

RSS feeds allow you to receive latest news and information about Boehringer Ingelheim.

subscribe to RSS Feed